Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink
![PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/eb56a0ed555af54134d5949c8b856bff15592fe4/3-Figure1-1.png "PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar")
PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar
Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy | Journal for ImmunoTherapy of Cancer | Full Text
The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC
Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer
Final overall survival (OS) data from FLAURA trial - YouTube
A) Overall survival (OS) in elderly patients ( 70 years) in relation... | Download Scientific Diagram
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy
Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
PSE investigates the correlation between OS and PFS at ESMO 2017
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
Kaplan-Meier survival curve for overall survival (OS) after total... | Download Scientific Diagram
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
Figure 1. Overall survival (OS) curve according to performance status(PS) of the study cohort of patients with advanced non-small cell lung cancer (mean OS of PS 0= 18.41, PS 1= 10.76, PS
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
![PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo](https://og.oa.mg/Progression%20Free%20Survival%20(PFS)%20and%20Overall%20Survival%20(OS)%20in%20Patients%20Receiving%203%20Targeted%20Therapies%20(TTS)%20for%20Metastatic%20Renal-Cell%20Carcinoma%20(MRCC).png?author=%20Roberto%20Iacovelli,%20Matteo%20Santoni,%20G.%20Di%20Lorenzo,%20L.%20Cerbone,%20Massimo%20Aglietta,%20Cristina%20Masini,%20Maria%20Olga%20Giganti,%20Caterina%20Messina,%20Cora%20N.%20Sternberg,%20G.%20Procopio "PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo")
PDF] Progression Free Survival (PFS) and Overall Survival (OS) in Patients Receiving 3 Targeted Therapies (TTS) for Metastatic Renal-Cell Carcinoma (MRCC) by Roberto Iacovelli, Matteo Santoni, G. Di Lorenzo, L. Cerbone, Massimo
